4 New Directions in Anxiolytic Drug Research

Progress in Medicinal Chemistry

Volumn 36, Issue C, 1999, Pages 169-200

  Scott, Malcolm K ^a   Demeter, David A ^a   Nortey, Samuel O ^a   Dubinsky, Barry ^a   Shank, Richard P ^a   Reitz, Allen B ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ANXIOLYTIC AGENT; BENZIMIDAZOLE DERIVATIVE; BENZODIAZEPINE DERIVATIVE; PYRIDONE DERIVATIVE;

ANXIETY DISORDER; HUMAN; METABOLISM; REVIEW; STRUCTURE ACTIVITY RELATION;

ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; BENZIMIDAZOLES; BENZODIAZEPINES; HUMANS; PYRIDONES; RECEPTORS, GABA-A; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0033289248     PISSN: 00796468     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0079-6468(08)70047-X     Document Type: Article

References (90)

1. Walley E.J., Beebe D.K., and Clark J.L. Am. Fam. Physician (1994) 1745-1753
2. Holister L.E. J. Clin. Psychopharmacol 46 (1986) 33-36 (Suppl.)
3. Jenike M.A. N. Engl. J. Med. 321 (1989) 539-541
4. Baldessarini R.J. In: Goodman L.S., and Gilman A. (Eds). Drugs and the Treatment of Psychiatric Disorders, in The Pharmacological Basis of Therapeutics. 7th ed. (1985), MacMillan Publishing Company, New York. 387-445
5. Randall L.O., Schallek W., Sternbach L.H., and Ning R.Y. Psychopharmacol. Agents III (1974) 175-281
6. Sussman N. J. Clin. Psychiatry 54 (1993) 44-51
7. Woods J.H., and Winger G. Psychopharmacology 118 (1995) 107-115
8. Bradwejn J. Can. J. Psychiatry 38 (1993) S109-S113
9. Papez J.W. Arch. Neurol. Psychiatry 38 (1937) 725-743
10. Stephenson F.A. Biochem J. 310 (1995) 1-9
11. Olsen R.W., and Tobin A.J. FASEB J. 4 (1990) 1469-1480
12. Burt D.R., and Kamatchi G.L. FASEB J. 5 (1991) 2916-2923
13. Doble A., and Martin I.L. Trends Pharmacol Sci. 13 (1992) 76-81
14. Chen S.W., Chen H.A., Davies M.F., and Loew G.H. Pharmacol. Biochem. Behav. 53 (1996) 87-97
15. Mehta A.K., and Shank R.P. Brain Res. 704 (1995) 289-297
16. Mehta A.K., and Shank R.P. Life Sci. 57 (1995) 2215-2222
17. McKernan R.M., and Whiting P.J. Trends Neurosci. 19 (1996) 139-142
18. Marcel D., Weissmann-Nanopolous D., Mach E., and Pujol J.F. Brain Res. Bull. 16 (1986) 573-576
19. Young W.S., and Kuhar M.J. J. Pharmacol. Exp. Ther. 212 (1980) 284-292
20. Shibata K., Kataoka Y., Gomita Y., and Ueki S. Brain Res. 234 (1982) 442-446
21. Scheel-Kruger J., and Petersen E.N. Eur. J. Pharmacol. 82 (1982) 115-116
22. Hodges H., Green S., and Glenn B. Psychopharmacology 92 (1987) 491-504
23. Shibata K., Kataoka Y., Yamashita K., and Ueki S. Brain Res. 372 (1986) 159-162
24. Hitchcock J., and Davis M. Behav. Neurosci. 100 (1986) 11-22
25. Tulinsky J., and Gammill R.B. Curr. Med. Chem. 3 (1994) 226-253
26. Sieghart W. Trends Pharmacol. Sci. 10 (1989) 407-411
27. Sigel E., Baur R., Trube G., Mohler H., and Malherbe P. Neuron 5 (1990) 703-711
28. Olsen R.W., and Tobin A.J. Curr. Opin. Ther. Pat. 3 (1990) 101-128
29. Pritchett D.B., Sontheimer H., Shivers B.D., Ymer S., Kettenmann H., Schofield P.R., and Seeburg P.H. Nature (London) 338 (1989) 582-585
30. Wisden W., Herb A., Wieland H., Keinanen K., Luddens H., and Seeburg P.H. FEBS Lett. 289 (1991) 227-230
31. Smith G.B., and Olsen R.W. Trends Pharmacol. Sci. 16 (1995) 162-168
32. Potokar J., and Nutt D.J. CNS Drugs 1 (1994) 305-315
33. Luddens H., Pritchett D.B., and Kohler M. Nature (London) 346 (1990) 648-651
34. Pritchett D.B., Luddens H., and Seeburg P.H. Science (Washington, D.C.) 245 (1989) 1389-1392
35. Stephenson F.A. Biochem. J. 310 (1995) 1-9
36. Pritchett D.B., and Seeburg P.H. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 1421-1425
37. Mihic S.J., Whiting P.J., Klein R.I., Wafford K.A., and Harris R.A. J. Biol. Chem. 269 (1994) 32768-32773
38. Tanaka H., Kirihara S., Yasumatsu H., Yakushiji T., and Nakao T. Eur. J. Med. Chem. 308 (1995) 859-868
39. Palluotto F., Carotti A., Casini G., Campagna F., Genchi G., Rizzo M., and DeSarro G.B. Bioorg. Med. Chem. 4 (1996) 269-273
40. Guerrini G., Costanzo A., Bruni F., Selleri S., Casilli L., Guisti L., Martini C., Lucacchini A., Malmberg Aiello P., and Ipponi A. Eur. J. Med. Chem. 31 (1996) 259-272
41. Colotta V., Catarzi D., Varano F., Melani F., Filacchioni G., Cecchi L., Galli A., and Costagli C. II Farmaco 51 (1996) 223-229
42. Gardner C.R. Drugs Future 14 (1988) 51-67
43. Villar H.O., Uyeno E.T., Toll L., Polgar W., Davies M.F., and Loew G.H. Mol. Pharmacol. 36 (1989) 589-600
44. Squires R.F., Benson D.I., Braestrup C., Coupet J., Klepner C.A., Myers V., and Beer B. Pharmacol. Biochem. Behav. 10 (1979) 825-830
45. Kulkarni S.K., and Mehta A.K. Drugs Today 21 (1985) 145-153
46. Muller W.E. The Scientific Basis of Psychiatry. In: Shepherd M. (Ed). The Benzodiazepine Receptor 3 (1987), Cambridge University Press, Cambridge. 1-175
47. Haefely W., Martin J.R., and Schoch P. Trends Pharmacol. Sci. 11 (1990) 452-456
48. Williams M., and Olsen R. Benzodiazepine Receptors and Tissue Function. In: Williams M., Glennon R.A., and Timmermans P.B.M.W.M. (Eds). Receptor Pharmacology and Function (1989), Marcel Dekker, New York. 385-413
49. Guidotti A., Antonacci M.D., Guisti P., Massotti M., Memo M., and Schlichting J.L. Advances in Biochemical Psychopharmacology. In: Biggio G., and Costa E. (Eds). GABA and Benzodiazepine Receptor Subtypes 46 (1990), Raven Press, New York. 73-87
50. Vicini S. Neuropsychopharmacology 4 (1991) 9-15
51. McKernan R.M., Quirk K., Prince R., Cox P.A., Gillard N.P., Ragan C.I., and Whiting P. Neuron 7 (1991) 667-676
52. Maguire P.A., Davies M.F., Villar H.O., and Loew G.H. Eur. J. Pharmacol. 214 (1992) 85-88
53. Im H.K., Im W.B., Hamilton B.J., Carter D.B., and Von Voigtlander P.F. Mol. Pharmacol. 44 (1993) 866-870
54. Mertens S., Benke D., and Mohler H. J. Biol. Chem. 268 (1993) 5965-5973
55. Majewska M.D., Harrison M.L., Schwartz R.D., Barker J.L., and Paul S.M. Science (Washington, D.C.) 232 (1986) 1004-1006
56. Gee K.W., and Lan N.C. Mol. Pharmacol. 40 (1991) 995-999
57. Puia G., Ducic I., Vicini S., and Costa E. Receptors Channels 1 (1993) 135-142
58. Upasani R.B., Yang K.C., Acosta-Burruel M., Konkoy C.S., McLellan J.A., Woodward R.M., Lan N.C., Carter R.B., and Hawkinson J.E. J. Med. Chem. 40 (1997) 73-84
59. Finn D.A., Phillips T.J., Okorn D.M., Chester J.A., and Cunningham C.L. Pharmacol. Biochem. Behav. 56 (1997) 261-264
60. Jordan A.D., Kordik C.P., Reitz A.B., and Sanfilippo P.J. Exp. Opin. Ther. Pat. 6 (1996) 1047-1060
61. File S.E. Pharmacol. Biochem. Behav. 58 (1997) 747-752
62. Kennett G.A., Bright F., Trail B., Blackburn T.P., and Sanger G.J. Neuropharma-cology 36 (1997) 707-712
63. Herve P., Rault S., Lancelot J.C., Robba M., Renard P., Delagrange P., Pfeiffer B., Caignard D.H., Misslin R., Guardiola-Lemaitre B., and Hamon M. J. Med. Chem. 40 (1997) 1808-1819
64. Tang A.H., Franklin S.R., Carter D.B., Sethy V.H., Needham L.M., Jacobsen E.J., and Von Voightlander P.F. Psychopharmacology 131 (1997) 255-263
65. Sethy V.H., and Wu H. Pharmacol. Biochem. Behav. 58 (1997) 609-613
66. Jacobsen E., TenBrink R.E., Stelzer L.S., Belonga K.L., Carter D.B., Im H.K., Wha B., Sethy V.H., and Tang A.H. J. Med. Chem. 39 (1996) 158-175
67. Martin J.R., Moreau J.L., and Jenck F. Drug Dev. Res. 36 (1995) 141-149
68. Medina J.H., Viola H., Wolfman C., Marder M., Wasowski C., Calvo D., and Paladini A.C. Neurochem. Res. 22 (1997) 419-425
69. Hasenoehrl R.U., Nichau C., Frisch C., Silva M.A., Huston J.P., Mattern C.M., and Haecker R. Pharmacol., Biochem. Behav. 53 (1996) 271-275
70. Vogel J.R., Beer B., and Clody D.E. Psychopharmacology 21 (1971) 1-7
71. Swinyard E.A. J. Am. Pharm. Assoc. 38 (1949) 201-204
72. Maryanoff B.E., Ho W., McComsey D.F., Reitz A.B., Grous P.P., Nortey S.O., Shank R.P., Dubinsky B., Taylor R.J., and Gardocki J.F. J. Med. Chem. 38 (1995) 16-20
73. Hughes D. Org. React. 42 (1962) 355-656
74. Tsunoda T., Yamamiya Y., and Ito S. Tetrahedron Lett. 34 (1993) 1639-1642
75. Tsunoda T., Otsuka J., Yamamiya Y., and Ito S. Chem. Lett (1994) 539-542
76. Maryanoff B.E., Ho W., McComsey D.F., Shank R.P., and Dubinsky B. Bioorg. Med. Chem. Lett. 6 (1996) 333-338
77. Maryanoff, B.E., McComsey, D.F. and Ho, W. (1997) U. S. Pat. 5,639,760.
78. Tripos Associates, 1699 S. Hanley Road, Suite 303, St. Louis, MO 63144, U.S.A.
79. Marshall G., Barry C., Bosshard H., Dammkoehler R., and Dunn D. In: Olson E.C., and Christofferson R.E. (Eds). The Confor-mational Parameter in Drug Design: The Active Analog Approach in Computer Assisted Drug Design 112 (1979), ACS Symposium Series, Washington, D.C. 205-226
80. Mayer D., Naylor C.B., Motoc I., and Marshall G.R. J. Comput.-Aided Mol. Design 1 (1987) 3-16
81. Clark M., Cramer III R., and Van Opdenbosch N. J. Comput. Chem. 10 (1989) 982-1012
82. Gasteiger J., and Marsili M. Tetrahedron 36 (1980) 3219-3228
83. Marsili M., and Gasteiger J. Croat. Chem. Acta 53 (1980) 601-614
84. Gasteiger J., and Marsili M. Org. Magn. Reson. 15 (1981) 353-360
85. Streitwieser A. Molecular Orbital Theory for Organic Chemists (1961), Wiley, N. Y.
86. Purcel W.P., and Singer J.A. J. Chem. Eng. Data 12 (1967) 235-246
87. Zhang W., Koehler K.F., Harris B., Skolnick P., and Cook J.M. J. Med. Chem. 37 (1994) 745-757
88. Personal communication with J.M. Cook, University of Wisconsin at Milwaukee.
89. Woods J.H., Katz J.L., and Winger G. Pharmacol. Rev. 44 (1992) 151-347
90. Woods J.H., Katz J.L., and Winger G. abc. In: Kupfer F.E., and Bloom D.J. (Eds). Abuse and Therapeutic Use of Benzodiazepines and Benzodiazepine-like Drugs in Psychopharmacology: The Fourth Generation of Progress (1995), Raven Press, New York. 1777-1791